Archive for 2010

Aspen ARV tender bid is successful

Aspen ARV tender bid is successfulFollowing the announcement of the Anti-Retroviral (ARV) Tender results by the South African National Treasury Department, Aspen Pharmacare Holdings Limited is pleased to announce that its South African operating company (Aspen) has been successful in winning a number of key products in the tender, including Efavirenz and Tenofovir, in spite…

Read More

Aspen’s CSI programmes provide increased ARV access to mothers and infants

Aspen’s CSI programmes provide increased ARV access to mothers and infants Johannesburg. Aspen Pharmacare, South Africa’s leading pharmaceutical manufacturer, as part of its continued social commitment programme has established an antiretroviral (“ARV”) dispensary and has contributed to the upgrading of critical theatre equipment at the Rahima Moosa Mother and Child Hospital (“RMMCH”) in Coronationville. Stavros…

Read More

Aspen’s Revenue increases by 20% to exceed R10 billion

Johannesburg – JSE Ltd listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer, has produced excellent results for the year ended 30 June 2010. The South African business was the leading driver of the growth achieved. GROUP PERFORMANCE: Group revenue increased by 20% to R10.147 billion (R8.441 billion). Group operating profit improved by 20% to…

Read More

Aspen Trading Update

By : Shauneen Beukes APN – Aspen Pharmacare Holdings Limited – Trading update Aspen Pharmacare Holdings Limited (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN & ISIN: ZAE000066692 (“Aspen”) Trading update Aspen shareholders are hereby advised that headline earnings per share, for the 12 months ended 30 June 2010, are…

Read More

Acquisition of Sigma Pharmaceuticals Limited by Aspen

By : Shauneen Beukes ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN ISIN: ZAE000066692 (“Aspen”) ANNOUNCEMENT REGARDING THE ACQUISITION OF THE PHARMACEUTICAL BUSINESS OF SIGMA PHARMACEUTICALS LIMITED (“SIGMA”) BY ASPEN 1. INTRODUCTION Aspen shareholders are referred to the detailed cautionary announcement released on the Securities Exchange…

Read More

Aspen Sigma SENS Cautionary Renewal

Aspen Pharmacare Holdings Limited (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN ISIN: ZAE000066692 (“Aspen”) Renewal of detailed cautionary announcement Aspen shareholders are referred to the detailed cautionary announcement dated 21 May 2010 and are advised that Aspen Global Incorporated (“Aspen Global”) has submitted to Sigma Pharmaceuticals Limited (“Sigma”), a…

Read More

Aspen and Strides restructure Oncology arrangements

Aspen Pharmacare Holdings Limited (“Aspen”), listed on the JSE, South Africa (share code APN) and Strides Arcolab Limited, today announced a restructuring of their arrangements relating to the two oncology joint ventures (“JVs”) between Aspen and Strides, Onco Therapies Limited (“OTL”), India and Onco Laboratories Limited (“OLL”), Cyprus. The transactions The following are the material…

Read More

Aspen raises profits by 31% as South African business shines

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded strong returns for the six months ended 31 December 2009. The excellent performance from the South Africa business underpinned the results. Group Performance: Group revenue increased by 10 percent to R4.576 billion (R4.142 billion). Group operating profit increased by 16 percent to R1.314…

Read More

Aspen Receives US $1 Million In Transfer of Technology Agreement

Johannesburg – Eli Lilly today announced the US$1 million milestone payment to Aspen, South Africa’s leading pharmaceutical manufacturer, as part of the joint collaboration on expanding access to medicines to treat multidrug-resistant tuberculosis (MDR-TB). The milestone is part of a Transfer of Technology agreement between Aspen and Lilly, initiated in 2003 under the umbrella of…

Read More